|
1
|
Dasari A, Shen C, Halperin D, Zhao B, Zhou
S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence,
and survival outcomes in patients with neuroendocrine tumors in the
United States. JAMA Oncol. 3:1335–1342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen
S, St Peter J, Cherfi A and Öberg KE: Chromogranin A and
neuron-specific enolase as prognostic markers in patients with
advanced pNET treated with everolimus. J Clin Endocrinol Metab.
96:3741–3749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Milan SA and Yeo CJ: Neuroendocrine tumors
of the pancreas. Curr Opin Oncol. 24:46–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT
and Chang JS: The epidemiology of neuroendocrine tumors in taiwan:
A nation-wide cancer registry-based study. PLoS One. 8:e624872013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burns WR and Edil BH: Neuroendocrine
pancreatic tumors: Guidelines for management and update. Curr Treat
Options Oncol. 13:24–34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Modlin IM, Gustafsson BI, Moss SF, Pavel
M, Tsolakis AV and Kidd M: Chromogranin A-biological function and
clinical utility in neuro endocrine tumor disease. Ann Surg Oncol.
17:2427–2443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lawrence B, Gustafsson BI, Kidd M, Pavel
M, Svejda B and Modlin IM: The clinical relevance of chromogranin A
as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am. 40(111–134): viii2011.
|
|
8
|
Vinik AI, Woltering EA, Warner RR, Caplin
M, O'Dorisio TM, Wiseman GA, Coppola D and Go VL: North American
Neuroendocrine Tumor Society (NANETS): NANETS consensus guidelines
for the diagnosis of neuroendocrine tumor. Pancreas. 39:713–734.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jilesen AP, Busch OR, van Gulik TM, Gouma
DJ and van Dijkum Nieveen EJ: Standard pre- and postoperative
determination of chromogranin a in resectable non-functioning
pancreatic neuroendocrine tumors-diagnostic accuracy: NF-pNET and
low tumor burden. Dig Surg. 31:407–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shanahan MA, Salem A, Fisher A, Cho CS,
Leverson G, Winslow ER and Weber SM: Chromogranin A predicts
survival for resected pancreatic neuroendocrine tumors. J Surg Res.
201:38–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH,
Hwang TL, Rau KM, Yeh KY, Chen TC and Sun CF: Chromogranin A is a
reliable biomarker for gastroenteropancreatic neuroendocrine tumors
in an Asian population of patients. Neuroendocrinology. 95:344–350.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han X, Zhang C, Tang M, Xu X, Liu L, Ji Y,
Pan B and Lou W: The value of serum chromogranin A as a predictor
of tumor burden, therapeutic response, and nomogram-based survival
in well-moderate nonfunctional pancreatic neuroendocrine tumors
with liver metastases. Eur J Gastroenterol Hepatol. 27:527–535.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hijioka M, Ito T, Igarashi H, Fujimori N,
Lee L, Nakamura T, Jensen RT and Takayanagi R: Serum chromogranin A
is a useful marker for Japanese patients with pancreatic
neuroendocrine tumors. Cancer Sci. 105:1464–1471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z,
Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, et al: Chromogranin A
is a reliable serum diagnostic biomarker for pancreatic
neuroendocrine tumors but not for insulinomas. BMC Endocr Disord.
14:642014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yung RC, Otell S, Illei P, Clark DP,
Feller-Kopman D, Yarmus L, Askin F, Gabrielson E and Li QK:
Improvement of cellularity on cell block preparations using the
so-called tissue coagulum clot method during endobronchial
ultrasound-guided transbronchial fine-needle aspiration. Cancer
Cytopathol. 120:185–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chatzipantelis P, Salla C, Konstantinou P,
Karoumpalis I, Sakellariou S and Doumani I: Endoscopic
ultrasound-guided fine-needle aspiration cytology of pancreatic
neuroendocrine tumors: A study of 48 cases. Cancer. 114:255–262.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive system:
World Health Organization. 2010.
|
|
18
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene F and Trotti A: AJCC Cancer Staging Manual. New York, NY:
Springer; 2010
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vinik AI, Silva MP, Woltering EA, Go VL,
Warner R and Caplin M: Biochemical testing for neuroendocrine
tumors. Pancreas. 38:876–889. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nölting S, Kuttner A, Lauseker M, Vogeser
M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Göke B and
Auernhammer CJ: Chromogranin a as serum marker for
gastroenteropancreatic neuroendocrine tumors: A single center
experience and literature review. Cancers (Basel). 4:141–155. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Campana D, Nori F, Piscitelli L,
Morselli-Labate AM, Pezzilli R, Corinaldesi R and Tomassetti P:
Chromogranin A: Is it a useful marker of neuroendocrine tumors? J
Clin Oncol. 25:1967–1973. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Walter T, Chardon L, Chopin-laly X,
Raverot V, Caffin AG, Chayvialle JA, Scoazec JY and Lombard-Bohas
C: Is the combination of chromogranin A and pancreatic polypeptide
serum determinations of interest in the diagnosis and follow-up of
gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer.
48:1766–1773. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cherenfant J, Stocker SJ, Gage MK, Du H,
Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, et
al: Predicting aggressive behavior in nonfunctioning pancreatic
neuroendocrine tumors. Surgery. 154:785–793. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Metz DC and Jensen RT: Gastrointestinal
neuroendocrine tumors: Pancreatic endocrine tumors.
Gastroenterology. 135:1469–1492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kishi Y, Shimada K, Nara S, Esaki M,
Hiraoka N and Kosuge T: Basing treatment strategy for
non-functional pancreatic neuroendocrine tumors on tumor size. Ann
Surg Oncol. 21:2882–2888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paik WH, Ryu JK, Song BJ, Kim J, Park JK,
Kim YT and Yoon YB: Clinical usefulness of plasma chromogranin a in
pancreatic neuroendocrine neoplasm. J Korean Med Sci. 28:750–754.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Korse CM, Taal BG, Vincent A, van
Velthuysen ML, Baas P, Buning-Kager JC, Linders TC and Bonfrer JM:
Choice of tumour markers in patients with neuroendocrine tumours is
dependent on the histological grade. A marker study of Chromogranin
A, Neuron specific enolase, Progastrin-releasing peptide and
cytokeratin fragments. Eur J Cancer. 48:662–671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jensen EH, Kvols L, McLoughlin JM, Lewis
JM, Alvarado MD, Yeatman T, Malafa M and Shibata D: Biomarkers
predict outcomes following cytoreductive surgery for hepatic
metastases from functional carcinoid tumors. Ann Surg Oncol.
14:780–785. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
de Laat JM, Pieterman CR, Weijmans M,
Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN,
Drent ML, Bisschop PH, Havekes B, et al: Low accuracy of tumor
markers for diagnosing pancreatic neuroendocrine tumors in multiple
endocrine neoplasia type 1 patients. J Clin Endocrinol Metab.
98:4143–4151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Granberg D, Stridsberg M, Seensalu R,
Eriksson B, Lundqvist G, Oberg K and Skogseid B: Plasma
chromogranin A in patients with multiple endocrine neoplasia type
1. J Clin Endocrinol Metab. 84:2712–2717. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Giusti M, Sidoti M, Augeri C, Rabitti C
and Minuto F: Effect of short-term treatment with low dosages of
the proton-pump inhibitor omeprazole on serum chromogranin A levels
in man. Eur J Endocrinol. 150:299–303. 2004. View Article : Google Scholar : PubMed/NCBI
|
